Effect of Treatment With Corifollitropin Alpha in Vitro Fertilization in Patients With Poor Ovarian Response.
Infertility
About this trial
This is an interventional treatment trial for Infertility focused on measuring Infertility, IVF, Corifollitropin Alfa treatment, Ovarian stimulation
Eligibility Criteria
Inclusion Criteria:
- - Age ≥ 18 years old.
- - Signed informed consent to perform IVF and participation in this study.
- Due to characteristics of our center not perform treatments in patients
40 years old ,and being one of the Bologna criteria that we will not be able to consider ,we decided to include patients affected subsidiary infertility treatment by IVF or intracytoplasmatic sperm injection (ICSI), present one of the following factors
- Have a history of surgical or medical treatment as a risk factor for POR.
- Patients witch had have a poor ovarian response in response to the ovarian controlled stimulation (previous cycle after conventional stimulation with ≤ 3 oocytes)
- Patients with ovarian reserve test anti-mullerian hormone(AMH ) <1.1 ng / ml (<8 pM) or antral follicle count (AFC)<7
Exclusion Criteria:
- -Anovulation.
- -Patient with tubal factor, untreated
- -Patient with uterine pathology untreated
- - Couples with severe male factor, fresh count <5 million / ml, and azoospermia in which the patient's sperm, epididymal or testicular is used
Sites / Locations
- Human Reproduction Unit of the La Fe University and Politechnic Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
CFA , hMG,Ganirelix,choriogonadotropin alfa,progesterone.
hMG ,Ganirelix,choriogonadotropin alfa,progesterone
Corifollitropin Alfa (CFA) 150 ug from the 2nd day of the cycle for 7 days. hMG 300 IU/24h, if required from the 8th day of the Controlled Ovarian Stimulation , until the day human chorionic gonadotropin ( hCG.) Ganirelix 0.25 mg,Dose: 250μg/24h since the day observe a follicle> 14mm. Recombinant choriogonadotropin alfa,Dose: 6,500 IU, pods, when follicles> 17 mm are observed. Micronized natural progesterone. Route of administration: vaginal. Dose: 400mg/24, from embryo transfer until the day of b-hCG.
Human Menopausal Gonadotropin (hMG). Dose: 300 IU/24h from the 2nd day of the cycle throughout the stimulation. Ganirelix 0.25 mg,Dose: 250μg/24h since the day observe a follicle> 14mm. Recombinant choriogonadotropin alfa,Dose: 6,500 IU, pods, when follicles> 17 mm are observed. Micronized natural progesterone. Route of administration: vaginal. Dose: 400mg/24, from embryo transfer until the day of b-hCG.